Answers are grounded in this paper and cite their sources.
This is a systematic review and meta-analysis of controlled trials evaluating phytoestrogens in women with natural peri- or postmenopause. The review examines the effects of phytoestrogens (isoflavones from soy, red clover and kudzu; genistein, daidzein and equol; flaxseed lignans; resveratrol; hop 8-prenylnaringenin; soy foods and fermented soy; and multicomponent preparations containing them) on outcomes in seven domains: climacteric symptoms, urogenital health, sexual function, neuropsychological outcomes, musculoskeletal health, cardiovascular health and metabolic health. Eligible designs are randomised (parallel or crossover) and non-randomised controlled studies published between 10 October 2016 and 10 October 2026. Placebo or no-treatment comparisons are analysed separately from active comparators (estrogen/hormone therapy, other phytoestrogen-containing products, and other active compounds). PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched; records were screened at title/abstract and full-text level, and reasons for exclusion were recorded. Risk of bias is assessed with RoB 2 and ROBINS-I. Effect sizes are Hedges’ g, pooled within each domain with three-level random-effects models (trials and effect sizes nested within trials) and cluster-robust variance estimation, only when at least three independent trials contribute. Subgroup analyses by phytoestrogen family and sensitivity analyses (established phytoestrogens only, all comparators combined, and inclusion of implausible effect sizes) are also reported. The review follows PRISMA 2020 and PRISMA-S.
No takes yet. Share an insight, caveat, or question.
Borrás et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: